Novel therapeutic agents in Waldenström's macroglobulinemia.
Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. irene_ghobrial@dfci.harvard.edu
Irene M
IM
Ghobrial
Xavier
X
Leleu
Abdel Kareem
AK
Azab
Judith
J
Runnels
Xiaoying
X
Jia
Hai
H
Ngo
Molly
M
Melhem
Feda
F
Azab
Antonio
A
Sacco
Phong
P
Quang
Nicholas
N
Burwick
Anne-Sophie
AS
Moreau
Emanuel
E
Husu
Mena
M
Farag
Aldo
A
Roccaro
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors